This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ABIO ARCA biopharma (ABIO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ARCA biopharma Stock (NASDAQ:ABIO) Get ARCA biopharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$2.40▼$599.0452-Week Range N/AVolume290,800 shsAverage Volume607,995 shsMarket Capitalization$34.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado. Read More Receive ABIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABIO Stock News HeadlinesOruka Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | tipranks.comHow to Watch General Tire 150: Live Stream ARCA Menards Series, TV ChannelJuly 18, 2025 | msn.comRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many. | Stansberry Research (Ad)Brenden ‘Butterbean’ Queen leads all laps, wins ARCA race at Dover Motor SpeedwayJuly 18, 2025 | msn.comDover weekend schedule, TV, weather info for NASCAR Cup, Xfinity and ARCAJuly 17, 2025 | msn.comHendrick Gambles Big on 20-Year-Old ARCA StarJuly 16, 2025 | msn.comSonoma weekend schedule, TV, weather info for NASCAR Cup, Xfinity and ARCAJuly 10, 2025 | msn.comThomas Annunziata overcomes early spin, wins ARCA Menards Series race at Lime Rock ParkJune 29, 2025 | msn.comSee More Headlines ABIO Stock Analysis - Frequently Asked Questions How were ARCA biopharma's earnings last quarter? ARCA biopharma, Inc. (NASDAQ:ABIO) released its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($48.96) EPS for the quarter, topping analysts' consensus estimates of ($341.28) by $292.32. When did ARCA biopharma's stock split? ARCA biopharma's stock reverse split on Tuesday, September 3rd 2024.The 1-12 reverse split was announced on Friday, August 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of ARCA biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARCA biopharma investors own include Digital Turbine (APPS), Vuzix (VUZI), Canoo (GOEV), ChargePoint (CHPT) and CrowdStrike (CRWD). Company Calendar Last Earnings8/04/2021Today10/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABIO CIK907654 Webarcabio.com Phone(720) 940-2100Fax720-208-9261Employees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.34 million Net MarginsN/A Pretax MarginN/A Return on Equity-20.18% Return on Assets-19.51% Debt Debt-to-Equity RatioN/A Current Ratio26.61 Quick Ratio26.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / BookN/AMiscellaneous Outstanding Shares14,507,000Free Float10,024,000Market Cap$34.82 million OptionableOptionable Beta0.91 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:ABIO) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredElon callingElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | SponsoredNvidia and AMD just surged. But this setup was already winning.Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARCA biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARCA biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
